The primary objective of the study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (MDD) and borderline personality disorder (BPD).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Montgomery-Asberg Depression Rating Scale (MADRS)
Timeframe: Baseline to Week 5
Borderline Personality Disorder Symptom Assessment Scale (BPD-SAS)
Timeframe: Baseline to Week 5